阿德福韦酯分别联合拉米夫定、恩替卡韦治疗乙型肝炎的临床观察

Clinical Observation of Using Adefovir Dipivoxil in Combination with Lamivudine and Entecavir respectively in Treating Hepatitis B

目的探讨阿德福韦酯分别与拉米夫定、恩替卡韦联合治疗慢性乙型肝炎的临床疗效,为临床提供治疗方案的选择。方法将270例慢性乙型肝炎型肝炎患者分为A、B两组,A组210例口服恩替卡韦0.5mg+阿德福韦酯10mg,1次/日;B组60例口服拉米夫定100mg+阿德福韦酯10mg,1次/日。结果在ALT、HBV-DNA复常率方面,A组与B组组间差异有统计学意义(P<0.05),而在HBeAg复常率方面组间差异无统计学意义(P>0.05)。结论在两种药物的应用方案中,A组疗效更确切。

Objective To select clinical project of treatment through evaluating clinical effects of treating chronic hepatitis B using Adefovir Dipivoxil combined with Lamivudine（LAM） and Entecavir（ETV） respectively. Methods We divided 270 patients of chronic hepatitis B into group A and B. In group A, 210 patients were taken ETV 0.5mg＋ADV 10mg orally, 1 time/day. In group B, 60 patients were taken LAM 100mg＋ADV 10mg orally, 1 time/day. Results Group A and B has significant difference（P0.05） in the recovery rate of ALT and HBV-DNA. There is no difference in the recovery rate of HBeAg. Conclusion The curative effect of group A is better between the two applications.